Puma Biotechnology has launched the phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202; NCT07465757) evaluating the investigational ...
Trispecific T-cell engagers target two tumor antigens or dual immune targets, aiming to reduce antigen-loss resistance and boost cancer killing beyond bispecifics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results